N-Substituted carbazolyloxyacetic acids modulate Alzheimer associated γ-secretase

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 1, 2007, Pages 176-182

  Narlawar, Rajeshwar ^a   Pérez Revuelta, Blanca I ^b   Baumann, Karlheinz ^c   Schubenel, Robert ^c   Haass, Christian ^b   Steiner, Harald ^b   Schmidt, Boris ^a  

^a DARMSTADT UNIVERSITY OF TECHNOLOGY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Alzheimer dementia; Aspartic protease; Modulator; Secretase

Indexed keywords

1 (METHYL) 7,7 DIMETHYLBICYCLO[2.2.1]HEPTAN 2 ONE CARBAZOLYLOXYACETIC ACID; 2 BROMOPHENYLCARBAZOLYLOXYACETIC ACID; 2,4,6 TRIISOPROPYLPHENYLCARBAZOLYLOXYACETIC ACID; 3 NITROPHENYLCARBAZOLYLOXYACETIC ACID; 3,5 BIS(TRIFLUOROMETHYL)PHENYLCARBAZOLYLOXYACETIC ACID; 3,5 DIFLUOROPHENYLCARBAZOLYLOXYACETIC ACID; 4 BIPHENYLCARBAZOLYLOXYACETIC ACID; 4 CHLOROPHENYLCARBAZOLYLOXYACETIC ACID; 4 METHYLPHENYLCARBAZOLYLOXYACETIC ACID; 4 N PROPYLPHENYLCARBAZOLYLOXYACETIC ACID; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; BMS 299897; BSC 2842; BSC 3041; CARBAZOLE DERIVATIVE; CARPROFEN; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; GLYCOLIC ACID DERIVATIVE; LUMIRACOXIB; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OCTYLCARBAZOLYLOXYACETIC ACID;

ALZHEIMER DISEASE; ARTICLE; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; ENZYME REGULATION; PROTEIN AGGREGATION; REDUCTION;

ACETIC ACIDS; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; HUMANS;

EID: 33845599845     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.09.061     Document Type: Article

References (35)

1. Mount C., and Downton C. Nat. Med. 12 (2006) 780
2. Schmidt B. ChemBioChem 4 (2003) 366
3. Schmidt B., Braun H.A., and Narlawar R. Curr. Med. Chem. 12 (2005) 1677
4. Chung H.-M., and Struhl G. Nat. Cell Biol. 3 (2001) 1129
5. Goutte C., Tsunozaki M., Hale V.A., and Priess J.R. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 775
6. Francis R., McGrath G., Zhang J., Ruddy D.A., Sym M., Apfeld J., Nicoll M., Maxwell M., Hai B., Ellis M.C., Parks A.L., Xu W., Li J., Gurney M., Myers R.L., Himes C.S., Hiebsch R., Ruble C., Nye J.S., and Curtis D. Dev. Cell 3 (2002) 85
7. Zhou S., Zhou H., Walian P.J., and Jap B.K. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 7499
8. Gu Y., Sanjo N., Chen F., Hasegawa H., Petit A., Ruan X., Li W., Shier C., Kawarai T., Schmitt-Ulms G., Westaway D., St. George-Hyslop P., and Fraser P.E. J. Biol. Chem. 279 (2004) 31329
9. Takasugi N., Tomita T., Hayashi I., Tsuruoka M., Niimura M., Takahashi Y., Thinakaran G., and Iwatsubo T. Nature 422 (2003) 438
10. Kimberly W.T., LaVoie M.J., Ostaszewski B.L., Ye W., Wolfe M.S., and Selkoe D.J. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 6382
11. De Strooper B., Annaert W., Cupers P., Saftig P., Craessaerts K., Mumm J.S., Schroeter E.H., Schrijvers V., Wolfe M.S., Ray W.J., Goate A., and Kopan R. Nature 398 (1999) 518
12. Wolfe M.S., Xia W., Ostaszewski B.L., Diehl T.S., Kimberly W.T., and Selkoe D.J. Nature 398 (1999) 513
13. Esler W.P., Kimberly W.T., Ostaszewski B.L., Diehl T.S., Moore C.L., Tsai J.-Y., Rahmati T., Xia W., Selkoe D.J., and Wolfe M.S. Nat. Cell Biol. 2 (2000) 428
14. Steiner H., Kostka M., Romig H., Basset G., Pesold B., Hardy J., Capell A., Meyn L., Grim M.L., Baumeister R., Fechteler K., and Haass C. Nat. Cell Biol. 2 (2000) 848
15. Churcher I., and Beher D. Curr. Pharm. Des. 11 (2005) 3363
16. Evin G., Sernee M.F., and Masters C.L. CNS Drugs 20 (2006) 351
17. in't Veld B.A., Ruitenberg A., Hofman A., Launer L.J., van Duijn C.M., Stijnen T., Breteler M.M.B., and Stricker B.H.C. N. Engl. J. Med. 345 (2001) 1515
18. McGeer P.L., Schulzer M., and McGeer E.G. Neurology 47 (1996) 425
19. Breitner J.C., Welsh K.A., Helms M.J., Gaskell P.C., Gau B.A., Roses A.D., Pericak-Vance M.A., and Saunders A.M. Neurobiol. Aging 16 (1995) 523
20. Aisen P.S., Luddy A., Durner M., Reinhard Jr. J.F., and Pasinetti G.M. J. Neurol. Sci. 161 (1998) 66
21. Schmidt, B.; Baumann, S.; Narlawar, R.; Braun, H. A.; Larbig, G. Neurodegen. Dis. 2006, 3, in press, doi:10.1159/000095269.
22. Narlawar R., Blanca P.R., Steiner H., Haass C., Schmidt B., and Baumann K. J. Med. Chem. 49 (2006) accepted for publication
23. Ricketts A.P., Lundy K.M., and Seibel S.B. Am. J. Vet. Res. 59 (1998) 1441
24. Koo, E. H. M.; Golde, T. E.; Galasko, D. R. WO 2001078721, 2001.
25. Stock N., Munoz B., Wrigley J.D.J., Shearman M.S., Beher D., Peachey J., Williamson T.L., Bain G., Chen W., Jiang X., St-Jacques R., and Prasit P. Bioorg. Med. Chem. Lett. 16 (2005) 2219
26. Peretto I., Radaelli S., Parini C., Zandi M., Raveglia L.F., Dondio G., Fontanella L., Misiano P., Bigogno C., Rizzi A., Riccardi B., Biscaioli M., Marchetti S., Puccini P., Catinella S., Rondelli I., Cenacchi V., Bolzoni P.T., Caruso P., Villetti G., Facchinetti F., DelGiudice E., Moretto N., and Imbimbo B.P. J. Med. Chem. 48 (2005) 5705
27. Barten D.M., Guss V.L., Corsa J.A., Loo A., Hansel S.B., Zheng M., Munoz B., Srinivasan K., Wang B., Robertson B.J., Polson C.T., Wang J., Roberts S.B., Hendrick J.P., Anderson J.J., Loy J.K., Denton R., Verdoorn T.A., Smith D.W., and Felsenstein K.M. J. Pharmacol. Exp. Ther. 312 (2005) 635
28. Beher, D.; Bettati, M.; Checksfield, G. D.; Churcher, I.; Doughty, V. A.; Oakley, P. J.; Quddus, A.; Teall, M. R.; Wrigley, J. D. WO 2005013985, 2005.
29. Sastre M., Steiner H., Fuchs K., Capell A., Multhaup G., Condron M.M., Teplow D.B., and Haass C. EMBO 2 (2001) 835
30. Larbig G., Zall A., and Schmidt B. Helv. Chim. Acta 87 (2004) 2334
31. Boehm H.-J., and Schneider G. Virtual Screening for Bioactive Molecules (2000), Wiley-VCH, Weinheim/New York
32. Brockhaus M., Grunberg J., Rohrig S., Loetscher H., Wittenburg N., Baumeister R., Jacobsen H., and Haass C. Neuroreport 9 (1998) 1481
33. 30
34. Cell toxicity assay. Cell viability was measured in the corresponding cells after removal of the media for the Aβ assays by a colourimetric cell proliferation assay (CellTiter 96TM AQ assay, Promega) utilizing the bioreduction of MTS (Owen's reagent) to formazan according to the manufacturer's instructions. Briefly, after removal of the supernatant for Aβ assays 80 μL of fresh cell culture medium was added to each well and incubated for 1 h before 20 μL MTS/PES solution was added. The optical density was recorded at 490 nm after 1 h incubation at 37 °C. Cell viability was expressed as % of untreated control.
35. Barltrop J.A., Owen T.C., Cory A.H., and Cory J.C. Bioorg. Med. Chem. Lett. 1 (1991) 611